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naive T cells, augmenting Th2 activity.
Interestingly, they reported that these cells
could be stimulated to produce IL-17 by
IL-1b, IL-6, and IL-21 but not by IL-23,
suggesting a distinct mechanism from
classical Th17-mediated release. The
same study found that in murine models
of allergic asthma, mice with allergen-
specific IL-17-producing Th2 cells exhibi-
ted increased airway inflammation
following allergen exposure, suggesting
some correlation between clinical
disease activity and stimulation of these
IL-17-producing Th2 T cells. Similarly, in
skin, Eyerich et al. (2009) used eczema
samples and identified that approximately
one-third of IL-17-producing cells exhi-
bited a concurrent Th0 or Th2 profile
(both IL-4-producing without or with
IFN-g, respectively). Thus, additional
studies, based on the work by Nakajima
et al. (2014), will be required to evaluate
the possibility that IL-17A is itself being
sourced from a subset of Th2 T cells
rather than from the classically pre-
sumed Th17 cells.
Upcoming targeted therapeutics for AD
may reveal further insights into the role of
cytokine interplay in disease pathogenesis
AD research has recently entered a new
era in which our collective understand-
ing of the immune mechanisms driving
disease has led to the development and
testing of agents targeting key molecules
in pathogenic pathways. A clinical trial
that is currently being conducted by
our group testing ustekinumab (anti-IL-
23p40) (clinicaltrials.gov, NCT01806662)
in AD patients may help elucidate the
effects of IL-17A inhibition on Th2
cytokine induction. By inhibiting Th17
T-cell activation (and thus significant
IL-17 production) with this biologic, we
will be able to evaluate the posttreat-
ment effects of such a blockade on all
the major inflammatory axes, including
Th2 T cells and their associated markers.
In doing so, our study may bridge the
murine work by Nakajima et al. (2014)
to humans, potentially providing insights
into whether IL-17 inhibition truly
reduces Th2 activity. Conversely, dupilu-
mab (clinicaltrials.gov, NCT01859988), a
mAb that inhibits IL-4Ra, dually block-
ing IL-4 and IL-13 signaling may shed
light on the effects of Th2 inhibition on
the IL-17 pathway genes in addition to
the other major T-cell axes. Moving
forward, a bedside-to-bench approach
with pathway-targeted therapeutics will
enable us to not only test the efficacies
of these drugs but also potentially unveil
additional novel targets in the major
inflammatory pathways. The work by
Nakajima et al. (2014) in this issue of
the journal, however, presents a fasci-
nating model for the initiation of Th2
inflammation in AD, providing a poten-
tial therapeutic target and an exciting
clue into the early stages of the slowly
unraveling AD pathogenesis model.
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Oxidative Stress and Vitiligo: The
Nrf2–ARE Signaling Connection
Lei Qiu1, Zhiqi Song1 and Vijayasaradhi Setaluri2
Hypersensitivity of epidermal melanocytes to oxidative stress is known to contribute
to vitiligo pathogenesis. Molecular mechanisms that connect melanocyte redox
homeostasis to the complex disease phenotype are not fully understood. Jian et al.
show that vitiligo melanocytes have impaired nuclear factor erythroid 2–related
factor 2 (Nrf2)–antioxidant response element signaling and decreased activation of
the antioxidant enzyme system. In patients with vitiligo, higher serum levels of IL-2
correlate with lower levels of hemeoxygenase-1, a product of the Nrf2 target gene.
Journal of Investigative Dermatology (2014) 134, 2074–2076. doi:10.1038/jid.2014.241
Degeneration of melanocytes, the cel-
lular source of melanin pigment, is the
pathologic hallmark of depigmented
macules in patients with vitiligo. Viti-
ligo is now recognized as a disorder of
multifactorial etiology culminating in
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melanocyte loss, although its underly-
ing pathogenic mechanisms are not
fully understood. Both intrinsic (gene
polymorphisms/mutations, autoimmu-
nity, autotoxicity of melanocytes, oxi-
dative stress) and extrinsic factors
(xenobioticsand infections) are known
to contribute to vitiligo, and it is recog-
nized that hypersensitivity to oxidative
stress has an important role in ultimate
destruction of epidermal melanocytes
(Taieb, 2000). Aberrant accumu-
lation of reactive oxygen species (ROS)
induced by oxidative insults disrupts
the redox homeostasis and eventually
contributes to its pathogenesis. In this
issue, Jian et al. (2014), using exposure
to hydrogen peroxide (H2O2) to
simulate oxidative stress, report on the
role of the nuclear factor erythroid 2–
related factor 2 (Nrf2)–antioxidant
response element (ARE) signaling path-
way in melanocyte homeostasis.
High levels of oxidative stress are
damaging to skin architecture, and
impaired cellular redox control is impli-
cated in many skin disorders. Recent
studies have demonstrated a crucial
function for the Nrf2–ARE signaling
pathway in regulating skin homeostasis
under oxidative stress (Marrot et al.,
2008). The Nrf2–ARE pathway is an
early sensor of oxidative stress, and it
acts to dampen oxidative damage by
upregulating the expression of phase II
detoxifying enzymes.
Nrf2, a basic leucine zipper transcrip-
tion factor with a Cap’n’ Collar structure,
is ubiquitously expressed in human
tissues. It regulates cellular defense
against oxidative stress by inducing the
expression of genes that code many
phase II detoxification enzymes (Kensler
et al., 2007). Phase II detoxification
enzymes, which convert metabolites to
species that are less reactive against cell
components, are critical components in
responses to oxidative stress. The ARE
sequence in the 50-flanking region of
many phase II detoxifying and antioxi-
dant genes is a promoter element to
which Nrf2 binds. In nonstressed cells,
Nrf2 is localized primarily in the cyto-
plasm owing to its binding to kelch-like
ECH-associated protein 1 (Keap1), which
negatively regulates Nrf2 function by
initiating its proteasomal degradation
(Itoh et al., 1999). Under oxidative
stress, dissociation of Nrf2 from and
Keap1 results in Nrf2 activation, its trans-
location and accumulation in the
nucleus. Binding of Nrf2 to AREs acti-
vates the expression of phase II enzymes
such as hemeoxygenase-1 (HO-1), cata-
lase, and superoxide dismutase. To
assess the role of the Nrf2–ARE pathway
in vitiligo in a previous study, Jian et al.
(2014) measured serum levels of anti-
oxidant enzymes in vitiligo patients
and compared them with age- and
sex-matched healthy controls.
In the present study, Jian et al. (2014)
demonstrate that vitiligo melanocytes
exhibit a diminished H2O2-induced oxi-
dative response as a result of impaired
Nrf2–ARE signaling. Using melanocytes
derived from control and vitiligo
patients, they first confirmed the hyper-
sensitivity of vitiligo melanocytes to
H2O2-induced oxidative insults in a
cell viability assay. When exposed to
H2O2, vitiligo melanocytes showed a
less prominent increase in HO-1 expres-
sion (both mRNA and protein) than did
control melanocytes. Nuclear trans-
location of Nrf2 from cytosol was also
impaired in the vitiligo melanocytes.
Impaired activation of antioxidant
enzymes and higher levels of cellular
oxidative stress were also detected,
confirming the correlation between
Nrf2–ARE signaling and oxidative stress
and its role in the destruction of mela-
nocytes in vitiligo.
Using normal human epidermal mel-
anocytes (PIG1), a vitiligo melanocyte
cell line (PIG3V), and promoter-reporter
assays, Jian et al. (2014) examined Nrf2
transcription factor activity upon induc-
tion of oxidative stress. As expected,
transcriptional activity of Nrf2 was signi-
ficantly lower in the PIG3V cell line
than in PIG1 cells. The most significant
observation of this study, however, was
that overexpression of Nrf2 (by trans-
fection with an Nrf2 expression plasmid)
restored antioxidative activity in PIG3V
cells. This observation supports an
important role for Nrf2 in regulating
the intracellular antioxidative capacity
of melanocytes.
To extend these in vitro observations
to patients and to search for an immu-
nological link to the oxidative stress, the
authors measured serum HO-1 and IL-2
levels in 113 nonsegmental vitiligo
patients and 113 healthy controls. They
found that, in patients with both stable
and progressive vitiligo, serum levels of
HO-1 were significantly lower, whereas
IL-2 levels were higher compared with
normal individuals, i.e., serum IL-2
levels were inversely proportional to
HO-1, an indicator of an oxidative stress
response. This was interesting in view of
previous studies that have shown HO-1,
through the production of carbon mon-
oxide, to suppress T-cell proliferation
via inhibition of IL-2 production (Pae
et al., 2004). Thus, the dampened Nrf2–
ARE signaling pathway may also
account for IL-2 activation in patients
with vitiligo. This will be an interesting
avenue for investigators to explore in
looking for a mechanistic link between
oxidative stress and immune activation
in vitiligo.
In summary, by confirming the anti-
oxidant function of the Nrf2–ARE path-
way in human melanocytes, Jian et al.
Clinical Implications
 The study by Jian et al. in this issue highlights the role of the nuclear factor
erythroid 2–related factor 2–antioxidant response element (Nrf2–ARE)
signaling pathway in protecting melanocytes from oxidative stress, and it
implicates an impaired Nrf2–ARE signaling response in melanocyte death
in patients with vitiligo.
 Inverse correlations between serum hemeoxygenase-1 and IL-2 levels
found in a large cohort of vitiligo patients suggest a link between impaired
oxidative damage and a heightened immune response.
 Evaluating and monitoring exposure to oxidative stress and developing
strategies to reduce oxidative stress may ultimately be included in the
preventive and therapeutic armamentarium for vitiligo.
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(2014) provide mechanistic insight into
the response of melanocytes to oxida-
tive stress and their role in the patho-
genesis of vitiligo. This study opens the
possibility that the Nrf2–ARE pathway
could be exploited as a preventive and/
or therapeutic strategy to counter oxida-
tive damage in melanocytes, as well as
to dampen IL-2 production.
There are several limitations to this
study, specifically as it relates to mela-
nocytes in vivo and the potential for
clinical translation. First, the melano-
cytes used in this study are immortalized
cell lines, which may exhibit altered
oxidative stress responses compared
with primary melanocytes. Immunohis-
tochemical evaluation of the levels/loca-
lization of Nrf2 and/or antioxidant
enzymes in normal and lesional skin
will be of considerable value. This will
also address the role of keratinocyte
antioxidant responses in vitiligo patho-
genesis, as keratinocytes are thought to
be ROS donors to melanocytes. Second,
although H2O2 is a widely used and
widely accepted oxidative stress indu-
cer, additional stressors may need to
be tested to confirm the role of the
Nrf2–ARE pathway. Third, although pro-
vocative, the observations on the inverse
relationship between serum HO-1 and
IL-2 levels do not identify the source of
HO-1 (melanocyte intracellular vs. sys-
temically derived) or the correlations
among serum HO-1, IL-2 levels, and
lesional T lymphocyte accumulation.
These limitations notwithstanding, this
study by Jian et al. (2014) shines a
spotlight on antioxdative mechanisms
in vitiligo and highlights the need to
explore strategies to restore a balanced
redox system, thereby protecting
melanocytes from destruction.
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Nagashima-Type Palmoplantar
Keratosis: A Common Asian Type
Caused by SERPINB7 Protease
Inhibitor Deficiency
Akiharu Kubo1
Nagashima-type palmoplantar keratosis (NPPK) is an autosomal recessive diffuse
non-epidermolytic palmoplantar keratosis caused by mutations in SERPINB7, a
member of the serine protease inhibitor superfamily. Genetic studies suggest that
NPPK is the most common palmoplantar keratosis in Japan, and probably Asia,
but one that is extremely rare in Western countries. In this issue, Yin et al. report a
founder effect of a SERPINB7 mutation in Chinese populations.
Journal of Investigative Dermatology (2014) 134, 2076–2079. doi:10.1038/jid.2014.156
Establishment of a new entity of
palmoplantar keratosis
Nagashima-type palmoplantar keratosis
(NPPK; MIM 615598) is a comparatively
new entity of palmoplantar keratosis
(PPK). Masaji Nagashima first described
this disease briefly in 1977 as a form of
PPK showing a similar distribution of
lesions to, but a considerably milder
disease phenotype than, Mal de Meleda
(MIM 248300) (Nagashima, 1977). Inde-
pendently, Mitsuhashi and Hashimato
(1989) observed a Japanese patient who
had reddish diffuse mild PPK extending
to the dorsal surfaces of the hands and
feet. Together with UW Schnyder, a
Swiss specialist in genetic skin diseases
who investigated Mal de Meleda in
the Adriatic island of Mljet (Meleda)
(Schnyder, 1969), they concluded that
the patient’s phenotype was far milder
than that of Mal de Meleda. Ultimately,
they reported siblings with the same
distinct disease phenotype and con-
cluded that the disease was a novel
autosomal recessive PPK, designating it
as ‘‘keratosis palmoplantaris Nagashima’’
(Mitsuhashi and Hashimato, 1989).
Because of its probable very low
prevalence in Western countries, this
disease entity has long been recognized
only in Japan. In 2008, Kabashima et al.
(2008) introduced NPPK to international
societies with a detailed description of
the disease phenotype, and they pro-
posed NPPK as a distinct clinical entity
because of the lack of mutations in the
exonic region of SLURP1, the causa-
tive gene of Mal de Meleda. In 2013,
Kubo et al. (2013) finally identified the
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